[{"Assets_0_Q3_USD":544475000.0,"CommonStockSharesOutstanding_0_Q3_shares":93973747.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-43069000.0,"NetIncomeLoss_1_Q3_USD":-35371000.0,"NetIncomeLoss_3_Q3_USD":-113773000.0,"StockholdersEquity_0_Q3_USD":461179000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":1195000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":3484000.0,"Ticker":"DNLI","CIK":"1714899","name":"DENALI THERAPEUTICS INC.","OfficialName":"Denali Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"3477413158.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20181108"}]